Irene Wessel

Irene Wessel

Auto-generated profile, based on publicly available information

Irene Wessel

Clinical Nutrition Center, Department of Transplantation and Digestive Diseases, Rigshospitalet, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in European Journal of Cancer
Verified
Journal Article
Open access
Giulia BertinoGiulia Bertino
Giulia Bertino
Gregor SersaGregor Sersa
Gregor Sersa
FTFrancesca De Terlizzi
Francesca De Terlizzi
AOAntonio Occhini
Antonio Occhini
CPChristina Caroline Plaschke
Christina Caroline Plaschke
MBMarco Benazzo
Marco Benazzo
Electrochemotherapy is an effective and safe method for local treatment of cutaneous and subcutaneous tumours, where electric pulses cause increased permeability of cell membranes in the tumour mass, enabling dramatically enhanced effectiveness of bleomycin and other hydrophilic drugs. Here, we report results of a European multi-institutional prospective study of the effectiveness of electrochemotherapy in the treatment of skin cancer of the head and neck (HN) area, where standard treatments had either failed or were not deemed suitable or declined by the patient. A total of 105 patients affected by primary or recurrent skin cancer of the HN area were enrolled; of these, 99 were eligible for evaluation of tumour response. By far, the majority (82%) were treated only once, and 18% of patients had a second treatment. The objective response was highest for basal cell carcinoma (97%) and for other histologies was 74%. Small, primary, and treatment-naive carcinomas responded significantly better (p < 0.05), as investigated by univariate analysis. Electrochemotherapy was well tolerated and led to a significant improvement of quality of life, estimated by the European Organisation for Research and Treatment of Cancer quality of life questionnaires. At 1-year follow-up, the percentages of overall and disease-free survival were 76% and 89%, respectively. Electrochemotherapy is an effective option for skin cancers of the HN area and can be considered a feasible alternative to standard treatments when such an alternative is appropriate. The precise role for electrochemotherapy in the treatment algorithm for non-melanoma skin cancer of the HN region requires data from future randomised controlled studies. (ISRCTN registry N. 30427).

1 December 2017 in European Journal of Cancer
Verified
Journal Article
Closed access
CPChristina Caroline Plaschke
Christina Caroline Plaschke
GBGiulia Bertino
Giulia Bertino
JMJames A. McCaul
James A. McCaul
JGJuan J. Grau
Juan J. Grau
RBRemco de Bree
Remco de Bree
Karen Julie GehlKaren Julie Gehl
Karen Julie Gehl

3 January 2019 in Laryngoscope Investigative Otolaryngology
Verified
Journal Article
Open access
PDF file
CPChristina Caroline Plaschke
Christina Caroline Plaschke
JGJulie Gehl
Julie Gehl
HJHelle Hjorth Johannesen
Helle Hjorth Johannesen
BFBarbara Malene Fischer
Barbara Malene Fischer
Andreas KjaerAndreas Kjaer
Andreas Kjaer
IWIrene Wessel
Irene Wessel
Background: Calcium electroporation is a novel cancer treatment, which combines temporary cell permeability from electroporation with a high influx of calcium intracellularly resulting in cancer cell necrosis.Methods: A phase I trial performing calcium electroporation on 6 patients suffering from recurrent head and neck cancer. In general anesthesia, intratumoral calcium injections were followed by electroporation. Safety was monitored by adverse events registration, serum Ca2+, ECG, and pain scores. Tumor response was measured on PET/MRI scans.Results: Procedures were performed without complications. No serious adverse events, signs of hypercalcemia, or cardiac arrhythmias were observed. Two months post‐treatment tumor responses on MRI: three partial responses, one stable disease, and two progression. Responses on PET: one partial metabolic disease, four with stable metabolic disease, and one not evaluable. One patient was without clinical evidence of disease after 12 months of observation.Conclusion: Calcium electroporation is feasible and safe in head and neck tumors. Clinical responses were observed in three of six patients, warranting further studies.Level of Evidence: Level 4

17 February 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
EKEva Kristine Ruud Kjær
Eva Kristine Ruud Kjær
JJJakob Myllerup Jensen
Jakob Myllerup Jensen
KJKathrine Kronberg Jakobsen
Kathrine Kronberg Jakobsen
GLGiedrius Lelkaitis
Giedrius Lelkaitis
IWIrene Wessel
Irene Wessel
CGChristian Gronhoj
Christian Gronhoj
Background: Comorbidity is presumed to impact survival of head and neck squamous cell cancer (HNSCC) patients. However, the prevalence and prognostic impact of comorbidity in these patients is not yet well established. The aim of this study is to outline the comorbidity burden of HNSCC patients and investigate the relation to overall survival and cancer-specific mortality.Methods: The comorbidity burden of patients registered with HNSCC in the Danish Cancer Registry between 1980 and 2014 was evaluated based on the Charlson Comorbidity Index (CCI). Patients’ risks of comorbid conditions compared to age- and gender-matched controls were estimated by odds ratios (OR). The impact of comorbidity on overall survival and cancer-specific mortality was evaluated by Cox regression and Kaplan-Meier survival analysis.Results: A total of 25,388 HNSCC patients were included (72.5% male; mean age 63.2 years at diagnosis; median follow-up 3.0 years). CCI at diagnosis was significantly higher in patients compared to controls (p &lt; 0.001). The most common comorbid conditions among the patients were additional non-metastatic malignancy (10.9%) and cerebrovascular disease (7.7%). Compared to controls, patients had higher odds of metastatic malignancy (OR: 4.65; 95% CI: 4.21–5.15; p &lt; 0.001), mild liver disease (OR: 6.95; 95% CI: 6.42–7.53; p &lt; 0.001), and moderate-severe liver disease (OR: 7.28; 95% CI: 6.14–8.65; p &lt; 0.001). The multivariate Cox analysis revealed increasing hazard ratios with increasing CCI and in coherence the Kaplan-Meier curves showed poorer overall survival and increased cancer-specific mortality in patients with higher CCI.Conclusion: HNSCC patients’ comorbidity burden was significantly greater compared to the general population and increased comorbidity was correlated with increased cancer-related mortality.

1 May 2002 in Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
LJLars H. Jensen
Lars H. Jensen
ARAxelle Renodon-Corniere
Axelle Renodon-Corniere
IWIrene Wessel
Irene Wessel
SLSeppo W. Langer
Seppo W. Langer
BSBirgitte Søkilde
Birgitte Søkilde
PJPeter B. Jensen
Peter B. Jensen
Maleimide, N-ethyl-maleimide (NEM), andN-methyl-maleimide (NMM) were identified as potent catalytic inhibitors of purified human topoisomerase IIα, whereas the ring-saturated analog succinimide was completely inactive. Catalytic inhibition was not abrogated by topoisomerase II mutations that totally abolish the effect of bisdioxopiperazine compounds on catalytic inhibition, suggesting a different mode of action by these maleimides. Furthermore, in DNA cleavage assay maleimide and NEM could antagonize etoposide-induced DNA double-strand breaks. Consistently, maleimide could antagonize the effect of topoisomerase II poisons in three different in vivo assays: 1) In an alkaline elution assay maleimide protected against etoposide-induced DNA damage. 2) In a band depletion assay maleimide reduced etoposide-induced trapping of topoisomerase IIα and β on DNA. 3) In a clonogenic assay maleimide antagonized the cytotoxicity of etoposide and daunorubicin on four different cell lines of human and murine origin. at-MDR cell lines with reduced nuclear topoisomerase IIα content are fully sensitive to maleimide, indicating that it is not a topoisomerase II poison in vivo. Our finding that topoisomerase II is sensitive to maleimide, NMM, and NEM but insensitive to succinimide demonstrates a strict requirement for the unsaturated ring bond for activity. We suggest that the observed antagonism in vitro and in vivo is caused by covalent modification of topoisomerase II cysteine residues reducing the amount of catalytically active enzyme sensitive to the action of topoisomerase II poisons.

27 May 2021 in Acta Oncologica
Verified
Journal Article
Open access
BLBenedicte Bitsch Lauritzen
Benedicte Bitsch Lauritzen
JJJakob Myllerup Jensen
Jakob Myllerup Jensen
CGChristian Gronhoj
Christian Gronhoj
IWIrene Wessel
Irene Wessel
Christian von BuchwaldChristian von Buchwald
Christian von Buchwald
This study aimed to systematically review the literature on the impact of delay in diagnosis and treatment of oral cavity cancer.PubMed and Embase were systematically searched for articles reportin...